Surgery Partners, Inc. (NASDAQ:SGRY) Shares Acquired by Versor Investments LP

Versor Investments LP lifted its holdings in Surgery Partners, Inc. (NASDAQ:SGRY - Free Report) by 450.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 46,200 shares of the company's stock after buying an additional 37,800 shares during the quarter. Versor Investments LP's holdings in Surgery Partners were worth $978,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Principal Financial Group Inc. purchased a new stake in Surgery Partners during the third quarter worth about $1,469,000. King Street Capital Management L.P. purchased a new stake in shares of Surgery Partners during the 3rd quarter worth approximately $46,748,000. Royce & Associates LP grew its holdings in shares of Surgery Partners by 12.2% in the 3rd quarter. Royce & Associates LP now owns 510,261 shares of the company's stock worth $16,451,000 after acquiring an additional 55,545 shares during the period. Geode Capital Management LLC increased its stake in Surgery Partners by 2.4% in the 3rd quarter. Geode Capital Management LLC now owns 1,864,346 shares of the company's stock valued at $60,117,000 after purchasing an additional 42,897 shares in the last quarter. Finally, Victory Capital Management Inc. raised its holdings in Surgery Partners by 140.4% during the third quarter. Victory Capital Management Inc. now owns 1,330,399 shares of the company's stock worth $42,892,000 after purchasing an additional 777,038 shares during the last quarter.

Surgery Partners Trading Down 0.3 %

SGRY traded down $0.08 during trading on Monday, hitting $24.00. The company's stock had a trading volume of 2,032,969 shares, compared to its average volume of 1,473,894. Surgery Partners, Inc. has a twelve month low of $19.50 and a twelve month high of $33.97. The firm's 50 day moving average price is $23.04 and its 200-day moving average price is $26.45. The company has a debt-to-equity ratio of 0.99, a current ratio of 1.80 and a quick ratio of 1.66. The stock has a market cap of $3.05 billion, a PE ratio of -50.00, a PEG ratio of 19.21 and a beta of 2.60.

Remove Ads

Surgery Partners (NASDAQ:SGRY - Get Free Report) last released its earnings results on Monday, March 3rd. The company reported $0.39 earnings per share for the quarter, topping the consensus estimate of $0.38 by $0.01. Surgery Partners had a positive return on equity of 2.85% and a negative net margin of 2.03%. On average, analysts expect that Surgery Partners, Inc. will post 0.67 earnings per share for the current year.

Insider Buying and Selling

In other Surgery Partners news, CEO Jason Eric Evans sold 26,520 shares of the business's stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $25.65, for a total transaction of $680,238.00. Following the completion of the sale, the chief executive officer now owns 560,698 shares of the company's stock, valued at approximately $14,381,903.70. The trade was a 4.52 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO David T. Doherty sold 13,641 shares of the business's stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $25.61, for a total value of $349,346.01. Following the sale, the chief financial officer now owns 108,862 shares of the company's stock, valued at $2,787,955.82. The trade was a 11.14 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 96,733 shares of company stock valued at $2,480,106. Insiders own 2.30% of the company's stock.

Analyst Ratings Changes

SGRY has been the subject of a number of research analyst reports. Macquarie restated an "outperform" rating and issued a $34.00 price target on shares of Surgery Partners in a research report on Tuesday, November 19th. Royal Bank of Canada dropped their target price on shares of Surgery Partners from $49.00 to $35.00 and set an "outperform" rating for the company in a report on Wednesday, November 20th. JPMorgan Chase & Co. cut their target price on shares of Surgery Partners from $38.00 to $28.00 and set a "neutral" rating for the company in a research report on Tuesday, December 3rd. Finally, Bank of America began coverage on shares of Surgery Partners in a research report on Monday, December 16th. They issued a "buy" rating and a $30.00 price target on the stock. One analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $36.56.

About Surgery Partners

Surgery Partners, Inc, together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery.